Virios Therapeutics Inc VIRI shares are trading higher by 27.7% to $1.10 Monday afternoon after the company announced a halt to at-the-market offering sales.
The company says it has instructed sales agent JonesTrading to halt sales under the Capital on Demand Sales Agreement. The decision is based on current market conditions and operational priorities.
The company says it remains focused on transitioning its Phase 3 development program for IMC-1, executing IMC-2's Long-COVID study and exploring partnership opportunities for both FM and LC programs.
According to data from Benzinga Pro, Virios Therapeutics has a 52-week high of $9.11 and a 52-week low of $0.22.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
